|

Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments

MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.

That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.

In this video, we will play the most important clips and offer some commentary where necessary.

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedStock #MNMD

Similar Posts

  • Red Light Holland CANNABIS Merger, Atai IPO, NUMI Uplists, MindMed & More (TRUFF, atai, Numi, MMED)

    LOTS of news happened this week, one of the major ones being Red Light Holland’s merger with a CANNABIS Company called Cresco. Other news we discuss in today’s segment is atai Life Sciences Nasdaq uplisting, MindMed’s new addition to the team, Numinus’ Uplisting and Field Trip’s upcoming financial results.

    Enjoy!

    Timestamps:

    0:00 – Intro
    1:00 – atai Life Sciences Nasdaq IPO
    2:56 -Red Light Holland Merging With A Cannabis Company & Acquisition
    7:26 -Numinus Wellness Uplists To The TSX
    8:45 – MindMed Appoints Peter Bergethon To Their Scientific Advisory Board
    10:36 – Field Trip’s Upcoming Financial Results

    Links:
    atai Life Sciences ( NASDAQ: atai)
    https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html

    Red Light Holland ( CSE: TRIP / OTC: TRUFF) Closes Acquisition of 80% of Happy Caps Mushroom Farm:
    https://ca.finance.yahoo.com/news/red-light-holland-closes-acquisition-122000805.html

    Red Light Holland is Merging with a Cannabis company called Creso Pharma to create The HighBrid Lab:
    https://www.newsfilecorp.com/release/87740/Creso-Pharma-and-Red-Light-Holland-Merge-to-Introduce-The-HighBrid-Lab-TM-a-Leading-Global-Psychedelics-x-Cannabis-Company-Specializing-in-Recreational-Products-Applied-Science-Technology-and-Innovation

    Numinus Wellness (OTC: LKYSF, TSX.V: NUMI) Uplists to Tier 1 on the TSX Venture Exchange:
    https://thecannabisstock.com/2021/06/18/numinus-wellness-gradu

    MindMed (NASDAQ: MNMD, NEO: MMED) Appoints Pharmaceutical Veteran, DR Peter Bergethon to their Scientific Advisory Board:
    https://www.prnewswire.com/news-releases/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-md-to-scientific-advisory-board-301314501.html

    Field Trip Health (OTC: FTRPF, TSX: FTRP) Will Release Financial Results for its fiscal fourth quarter and full year 2021 ended March 31, 2021:
    https://ca.movies.yahoo.com/field-trip-health-ltd-announces-131000469.html
    https://www.meetfieldtrip.com/news/news-details/2021/Field-Trip-Health-Ltd.-Schedules-Fiscal-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Conference-Call-for-Friday-June-25-2021-At-800-am-ET/default.aspx

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    editing:@themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #RedLightHolland #MindMed #atai

  • MindMed Conference Call Recap & My THOUGHTS (MMED / MNMD)

    Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:

    1. MindMed’s Mission
    2. Their Talent acquisition
    3. The Progress of their different clinical trials
    4. The future

    Timestamps:
    0:00 – Intro
    1:59 – MindMed’s Mission
    4:36 – MMED’s talent acquisition
    7:24 – MindMed’s clinical trial progress
    10:48 – Psychiatry department : Project Lucy
    14:17 – Addiction department : Project Layla (18MC)
    18:33 – Pain department: Project Angie to treat pain card
    22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
    23:43 – MindMed (MMED / MNMD) and its future plans

    Enjoy!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MNMD

  • Interview with Trevor Millar, Advisor, NeonMind Biosciences

    In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle obesity. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese. 

  • Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn

    In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.

    In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.

    From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.

    Perhaps, psychedelics can treat mental health issues in general.

    Perhaps, ketamine can be used to heal.

    In the conversation, MDMA to treat addiction was also discussed.

    Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.

    With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.

    From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.

    #Psychedelics #Awakn #PsychedelicStocks